With providers delivering approximately 5 million Hydrafacial treatments last year 1, our position as one of the most in-demand professional skin health treatments is clear,” said BeautyHealth Chief ...

Streamex is a wholly owned subsidiary of BioSig Technologies, Inc., a medical device technology company with an advanced digital signal processing technology platform, the PURE EP™ Platform, that ...

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes ...

As previously announced, the FDA also granted iopofosine I 131 Fast Track Designation and Orphan Drug Designation. The European Medicines Agency (EMA) granted Orphan Drug Designation to iopofosine I ...

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, ...

Evaluation of AZD5658 expands Conduit’s glucokinase activator platform into novel veterinary applications, complementing AZD1656 development Cost-efficient approach enhances Conduit’s pipeline while ...

Vafseo ® (vadadustat) was approved by the U.S. Food and Drug Administration in March 2024 for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at ...

Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, and Rosy Wellness, a pioneering digital platform ...

Alvotech (NASDAQ: ALVO, ALVO-SDB), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has completed its transaction with Xbrane ...

HCW Biologics earned upfront payment and will recognize revenue of $7.0 million in Q2 2025 ...

FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”) today announced that it has executed an ...

Under the terms of the definitive agreement, BrainsWay will invest $5 million in Stella, and will receive a minority position in the company in the form of a preferred, annually compounding security.